DAMICO JENNIFER B.

SEC source: 0001225208-26-007004 · doc4.xml · nonDerivative · entry 1

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,611

SEC source: 0001225208-26-005911 · doc4.xml · nonDerivative · entry 1

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,397

SEC source: 0001225208-26-003318 · doc4.xml · nonDerivative · entry 3

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,934

F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon).

SEC source: 0001225208-26-003318 · doc4.xml · derivative · entry 4

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,638

Underlying: Common Stock · 22,638 shares

Expires 2031-03-03

F3 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F3 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

SEC source: 0001225208-26-003318 · doc4.xml · nonDerivative · entry 2

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,760

F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements.

SEC source: 0001225208-26-003318 · doc4.xml · nonDerivative · entry 1

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,352

F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements.

SEC source: 0001225208-26-002921 · doc4.xml · nonDerivative · entry 1

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,041

F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon).

SEC source: 0001225208-26-002819 · doc4.xml · derivative · entry 4

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,558 shares

Expires 2026-02-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-26-002819 · doc4.xml · nonDerivative · entry 3

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,696

F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).

F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.

SEC source: 0001225208-26-002819 · doc4.xml · nonDerivative · entry 2

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,383

F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.

SEC source: 0001225208-26-002819 · doc4.xml · nonDerivative · entry 1

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,744

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).

SEC source: 0001225208-26-002481 · doc4.xml · nonDerivative · entry 1

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,186

F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon).

SEC source: 0001225208-25-003073 · doc4.xml · derivative · entry 4

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,511

Underlying: Common Stock · 47,511 shares

Expires 2030-03-04

F3 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F3 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

SEC source: 0001225208-25-003073 · doc4.xml · nonDerivative · entry 3

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,850

SEC source: 0001225208-25-003073 · doc4.xml · nonDerivative · entry 2

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,350

F2 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements.

SEC source: 0001225208-25-002710 · doc4.xml · derivative · entry 4

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 22,416 shares

Expires 2025-02-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-25-002710 · doc4.xml · nonDerivative · entry 3

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,516

F3 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).

F4 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.

SEC source: 0001225208-25-002710 · doc4.xml · nonDerivative · entry 2

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,510

F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.

SEC source: 0001225208-25-002710 · doc4.xml · nonDerivative · entry 1

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,063

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).

SEC source: 0001225208-25-003073 · doc4.xml · nonDerivative · entry 1

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,761

F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon).

SEC source: 0001225208-25-002702 · doc4a.xml · nonDerivative · entry 1

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,647

F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon).

SEC source: 0001225208-25-002412 · doc4.xml · nonDerivative · entry 4

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,024

F6 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon).

F3 · price: Price is the closing price of Pfizer common stock on February 21, 2025.

SEC source: 0001225208-25-002412 · doc4.xml · derivative · entry 5

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,741 shares

Expires 2025-02-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001225208-25-002412 · doc4.xml · nonDerivative · entry 3

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,414

F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).

F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.

SEC source: 0001225208-25-002412 · doc4.xml · nonDerivative · entry 2

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,212

F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.

F3 · price: Price is the closing price of Pfizer common stock on February 21, 2025.

SEC source: 0001225208-25-002412 · doc4.xml · nonDerivative · entry 1

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,602

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).

SEC source: 0001225208-24-008699 · doc4.xml · derivative · entry 4

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,623

Underlying: Common Stock · 11,623 shares

Expires 2029-02-24

F1 · shares: Represents the number of shares of issuer common stock underlying stock appreciation rights ("total shareholder return units" or "TSRUs") eligible for modification ("Eligible TSRUs") pursuant to the issuer's one-time offer to modify Eligible TSRUs (the "Modification Offer") described in the Tender Offer Statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on August 12, 2024 (as amended, the "Schedule TO") that the reporting person elected to modify. The Modification Offer provided eligible participants the opportunity to elect to modify certain outstanding TSRUs to extend the dates upon which the awards vest and settle by two years (the "Modified TSRUs"). The grant price and number of shares underlying the Modified TSRUs remain unchanged.

F2 · derivative.expiration_date: Reflects a modification to the settlement date of the Modified TSRUs pursuant to the Modification Offer. The grant price and number of shares underlying the Modified TSRUs remain unchanged.

SEC source: 0001225208-24-008699 · doc4.xml · derivative · entry 3

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,623 shares

Expires 2027-02-24

F1 · shares: Represents the number of shares of issuer common stock underlying stock appreciation rights ("total shareholder return units" or "TSRUs") eligible for modification ("Eligible TSRUs") pursuant to the issuer's one-time offer to modify Eligible TSRUs (the "Modification Offer") described in the Tender Offer Statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on August 12, 2024 (as amended, the "Schedule TO") that the reporting person elected to modify. The Modification Offer provided eligible participants the opportunity to elect to modify certain outstanding TSRUs to extend the dates upon which the awards vest and settle by two years (the "Modified TSRUs"). The grant price and number of shares underlying the Modified TSRUs remain unchanged.

SEC source: 0001225208-24-008699 · doc4.xml · derivative · entry 2

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,169

Underlying: Common Stock · 12,169 shares

Expires 2030-02-23

F1 · shares: Represents the number of shares of issuer common stock underlying stock appreciation rights ("total shareholder return units" or "TSRUs") eligible for modification ("Eligible TSRUs") pursuant to the issuer's one-time offer to modify Eligible TSRUs (the "Modification Offer") described in the Tender Offer Statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on August 12, 2024 (as amended, the "Schedule TO") that the reporting person elected to modify. The Modification Offer provided eligible participants the opportunity to elect to modify certain outstanding TSRUs to extend the dates upon which the awards vest and settle by two years (the "Modified TSRUs"). The grant price and number of shares underlying the Modified TSRUs remain unchanged.

F2 · derivative.expiration_date: Reflects a modification to the settlement date of the Modified TSRUs pursuant to the Modification Offer. The grant price and number of shares underlying the Modified TSRUs remain unchanged.

SEC source: 0001225208-24-008699 · doc4.xml · derivative · entry 1

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,169 shares

Expires 2028-02-23

F1 · shares: Represents the number of shares of issuer common stock underlying stock appreciation rights ("total shareholder return units" or "TSRUs") eligible for modification ("Eligible TSRUs") pursuant to the issuer's one-time offer to modify Eligible TSRUs (the "Modification Offer") described in the Tender Offer Statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on August 12, 2024 (as amended, the "Schedule TO") that the reporting person elected to modify. The Modification Offer provided eligible participants the opportunity to elect to modify certain outstanding TSRUs to extend the dates upon which the awards vest and settle by two years (the "Modified TSRUs"). The grant price and number of shares underlying the Modified TSRUs remain unchanged.

SEC source: 0001225208-24-008041 · doc4.xml · derivative · entry 1

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,312

Underlying: Common Stock · 52 shares

Expires not disclosed

F1 · derivative.exercise_price: Each unit represents one phantom share of common stock.

F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

SEC source: 0001225208-24-008006 · doc4.xml · nonDerivative · entry 1

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,582

SEC source: 0001225208-24-007793 · doc4.xml · derivative · entry 1

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,223

Underlying: Common Stock · 49 shares

Expires not disclosed

F1 · derivative.exercise_price: Each unit represents one phantom share of common stock.

F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

SEC source: 0001225208-24-007463 · doc4.xml · derivative · entry 1

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,794

Underlying: Common Stock · 52 shares

Expires not disclosed

F1 · derivative.exercise_price: Each unit represents one phantom share of common stock.

F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

SEC source: 0001225208-24-007405 · doc4.xml · derivative · entry 1

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,745

Underlying: Common Stock · 222 shares

Expires not disclosed

F1 · derivative.exercise_price: Each unit represents one phantom share of common stock.

F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

SEC source: 0001225208-24-007064 · doc4.xml · derivative · entry 1

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,525

Underlying: Common Stock · 54 shares

Expires not disclosed

F1 · derivative.exercise_price: Each unit represents one phantom share of common stock.

F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

SEC source: 0001225208-24-006887 · doc4.xml · derivative · entry 1

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,475

Underlying: Common Stock · 51 shares

Expires not disclosed

F1 · derivative.exercise_price: Each unit represents one phantom share of common stock.

F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

SEC source: 0001225208-24-006587 · doc4.xml · derivative · entry 1

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,397

Underlying: Common Stock · 49 shares

Expires not disclosed

F1 · derivative.exercise_price: Each unit represents one phantom share of common stock.

F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

SEC source: 0001225208-24-006071 · doc4.xml · derivative · entry 1

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,346

Underlying: Common Stock · 49 shares

Expires not disclosed

F1 · derivative.exercise_price: Each unit represents one phantom share of common stock.

F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

SEC source: 0001225208-24-005424 · doc4.xml · derivative · entry 1

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,920

Underlying: Common Stock · 55 shares

Expires not disclosed

F1 · derivative.exercise_price: Each unit represents one phantom share of common stock.

F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

SEC source: 0001225208-24-005065 · doc4.xml · derivative · entry 1

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,864

Underlying: Common Stock · 54 shares

Expires not disclosed

F1 · derivative.exercise_price: Each unit represents one phantom share of common stock.

F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

SEC source: 0001225208-24-005034 · doc4.xml · derivative · entry 1

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,806

Underlying: Common Stock · 108 shares

Expires not disclosed

F1 · derivative.exercise_price: Each unit represents one phantom share of common stock.

F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

SEC source: 0001225208-24-004695 · doc4.xml · derivative · entry 1

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,686

Underlying: Common Stock · 49 shares

Expires not disclosed

F1 · derivative.exercise_price: Each unit represents one phantom share of common stock.

F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

SEC source: 0001225208-24-004294 · doc4.xml · derivative · entry 1

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,635

Underlying: Common Stock · 87 shares

Expires not disclosed

F1 · derivative.exercise_price: Each unit represents one phantom share of common stock.

F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

SEC source: 0001225208-24-003197 · doc4.xml · derivative · entry 3

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,404

Underlying: Common Stock · 17,404 shares

Expires 2031-02-27

F3 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.

F3 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.

SEC source: 0001225208-24-003197 · doc4.xml · derivative · entry 2

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,697

Underlying: Common Stock · 19,697 shares

Expires 2029-02-27

F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

SEC source: 0001225208-24-003197 · doc4.xml · nonDerivative · entry 1

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,495

F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements.

SEC source: 0001225208-24-003050 · doc4.xml · nonDerivative · entry 6

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,382

F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon).

F6 · price: Price is the closing price of Pfizer common stock on February 23, 2024.

SEC source: 0001225208-24-003050 · doc4.xml · nonDerivative · entry 5

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,768

F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon).

F6 · price: Price is the closing price of Pfizer common stock on February 23, 2024.

SEC source: 0001225208-24-003050 · doc4.xml · derivative · entry 7

DAMICO JENNIFER B. · CIK 0001805617 · SVP & Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,752 shares

Expires 2024-02-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.